IQV Strangle Strategy
IQV (IQVIA Holdings Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NYSE.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services.
IQV (IQVIA Holdings Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $39.79B, a trailing P/E of 29.39, a beta of 1.18 versus the broader market, a 52-week range of 154.5-251.36, average daily share volume of 1.6M, a public-listing history dating back to 2013, approximately 94K full-time employees. These structural characteristics shape how IQV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.18 places IQV roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on IQV?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
IQV snapshot
As of August 14, 2026, spot at $236.57, ATM IV 31.40%, IV rank 20.76%, expected move 9.00%. The strangle on IQV below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on IQV specifically: IQV IV at 31.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a IQV strangle, with a market-implied 1-standard-deviation move of approximately 9.00% (roughly $21.30 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IQV expiries trade a higher absolute premium for lower per-day decay. Position sizing on IQV should anchor to the underlying notional of $236.57 per share and to the trader's directional view on IQV stock.
IQV strangle setup
The IQV strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IQV at $236.57 on that close, the first option leg uses a $250.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IQV chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IQV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $250.00 | $4.55 |
| Buy 1 | Put | $220.00 | $3.13 |
IQV strangle risk and reward
- Net Premium / Debit
- -$767.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$767.50
- Breakeven(s)
- $212.33, $257.68
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IQV strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IQV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$21,231.50 |
| $52.32 | -77.9% | +$16,000.92 |
| $104.62 | -55.8% | +$10,770.33 |
| $156.93 | -33.7% | +$5,539.75 |
| $209.23 | -11.6% | +$309.17 |
| $261.54 | +10.6% | +$386.41 |
| $313.84 | +32.7% | +$5,617.00 |
| $366.15 | +54.8% | +$10,847.58 |
| $418.46 | +76.9% | +$16,078.16 |
| $470.76 | +99.0% | +$21,308.75 |
When traders use strangle on IQV
Strangles on IQV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IQV chain.
IQV thesis for this strangle
The market-implied 1-standard-deviation range for IQV extends from approximately $215.27 on the downside to $257.87 on the upside. A IQV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IQV IV rank near 20.76% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IQV at 31.40%. As a Healthcare name, IQV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IQV-specific events.
IQV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IQV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IQV alongside the broader basket even when IQV-specific fundamentals are unchanged. Always rebuild the position from current IQV chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IQV?
- A strangle on IQV is the strangle strategy applied to IQV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IQV stock at $236.57 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed IQV chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are IQV strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IQV strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 31.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$767.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IQV strangle?
- The breakeven for the IQV strangle priced on this page is roughly $212.33 and $257.68 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The IQV market-implied 1-standard-deviation expected move in the same options snapshot is approximately 9.00%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IQV?
- Strangles on IQV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IQV chain.
- How does current IQV implied volatility affect this strangle?
- IQV ATM IV is at 31.40% with IV rank near 20.76%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.